Article: Synaptic Licenses Preclinical Receptor Compounds To P&G.

Washington Editor

Synaptic Pharmaceutical Corp. said it granted Procter & Gamble Pharmaceuticals Inc. an exclusive patent license for two of its alpha-2 adrenergic receptor compounds.

The agreement also allows Cincinnati-based Procter & Gamble to operate under Synaptic's patents for all therapeutic indications for the two compounds.

Kathleen Mullinix, president and CEO of Paramus, N.J.-based Synaptic, told BioWorld Today that she couldn't discuss specific indications P&G is planning to study. The research is in the preclinical stage. She did say P&G will pay an up-front licensing fee plus milestones and royalties if a product is commercialized. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!